List of Excipients in Branded Drug SERTRALINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alvogen Inc	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	47781-951	CELLULOSE, MICROCRYSTALLINE
Alvogen Inc	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	47781-951	CROSCARMELLOSE SODIUM
Alvogen Inc	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	47781-951	FD&C YELLOW NO. 5
Alvogen Inc	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	47781-951	GELATIN
Alvogen Inc	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	47781-951	HYDROXYPROPYL CELLULOSE
Alvogen Inc	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	47781-951	MAGNESIUM STEARATE
Alvogen Inc	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	47781-951	SILICON DIOXIDE

Generic Drugs Containing SERTRALINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
West-ward Pharmaceutical Corp	sertraline hydrochloride	0143-9582	CELLULOSE, MICROCRYSTALLINE
West-ward Pharmaceutical Corp	sertraline hydrochloride	0143-9582	D&C YELLOW NO. 10
West-ward Pharmaceutical Corp	sertraline hydrochloride	0143-9582	FD&C BLUE NO. 2
West-ward Pharmaceutical Corp	sertraline hydrochloride	0143-9582	FERRIC OXIDE YELLOW
West-ward Pharmaceutical Corp	sertraline hydrochloride	0143-9582	MAGNESIUM STEARATE
West-ward Pharmaceutical Corp	sertraline hydrochloride	0143-9582	POLYETHYLENE GLYCOL
West-ward Pharmaceutical Corp	sertraline hydrochloride	0143-9582	POLYVINYL ALCOHOL

What are the Most Frequently-Used Excipients in SERTRALINE HYDROCHLORIDE?

# Of NDCs	Excipient
3	ALCOHOL
3	ALUMINUM OXIDE
1	AMMONIA
42	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	ANHYDROUS LACTOSE
8	ASCORBIC ACID
1	BUTYL ALCOHOL

Excipient Strategy and Commercial Opportunities for Sertraline Hydrochloride

Last updated: February 25, 2026

What are the key excipient considerations for sertraline hydrochloride formulations?

Formulating sertraline hydrochloride requires selecting excipients that optimize stability, bioavailability, and manufacturing efficiency. Common excipients include fillers like microcrystalline cellulose, binders such as povidone, disintegrants including croscarmellose sodium, and film-coating agents like hypromellose. The choice depends on the dosage form—immediate-release tablets are typical; alternatives include sustained-release capsules or liquid formulations for specific patient populations.

Critical excipient attributes:

• Compatibility with sertraline hydrochloride to prevent degradation
• Approval status with regulatory agencies (FDA, EMA)
• Impact on dissolution profile and bioavailability
• Packability and stability under various storage conditions

Manufacturers often incorporate lactose monohydrate as a diluent, but lactose intolerance considerations lead to alternatives such as microcrystalline cellulose or hypromellose-based lactose-free formulations.

How does excipient selection influence formulation development and market differentiation?

Excipient selection affects manufacturing reproducibility and shelf life, influencing regulatory approval and market access. Innovating excipient systems—like using novel disintegrants or controlled-release polymers—can create differentiated products with improved patient compliance or extended patent protection.

For example, controlled-release matrices with specific polymers (e.g., ethylcellulose) enable once-daily dosing, appealing for chronic therapy. Such formulations can command premium pricing, increasing profitability.

What are the commercial opportunities linked to excipient advancements for sertraline hydrochloride?

Key opportunities include:

• Enhanced Formulation Stability: Novel excipients that improve chemical stability enable longer shelf lives, reducing waste and recall risks.
• Patient-Centric Dosage Forms: Development of low-excipient or allergen-free formulations expands patient access, especially in sensitive populations.
• Extended-Release Technologies: Patented controlled-release systems justify higher pricing and market share.
• Cost Reduction: Efficient excipient blends reduce manufacturing costs, enhancing margins, especially in high-volume markets.
• Biosimilar and Generic Expansion: Differentiating excipient profiles facilitate regulatory approvals and patent challenges.

Insights from recent regulatory trends and patent landscapes

Regulatory agencies emphasize excipient transparency and safety profiles [1]. Companies investing in proven, well-characterized excipients enhance approval likelihood.

Patent landscapes reveal incremental innovations in excipient technology, with active filings focusing on controlled-release systems, moisture barriers, and taste-masking excipients. Generics firms increasingly adopt excipient modifications to navigate patent litigations and extend market exclusivity [2].

Strategic considerations for pharmaceutical companies

• Invest in novel excipient research to extend product life cycles
• Develop flexible formulations adaptable across multiple markets
• Engage with excipient suppliers for early access to new technologies
• Focus on regulatory compliance and documentation to expedite approval processes
• Leverage patent protections on proprietary excipient systems for market differentiation

Summary of formulation and commercial opportunities

Opportunity	Description	Market Impact
Controlled-release systems	Use of advanced polymers for once-daily dosing	Higher-priced, patient-friendly drugs
Excipient innovation	Novel stabilizers or disintegrants	Longer shelf life, better stability
Cost optimization	Streamlined excipient blends for manufacturing efficiency	Lower costs, higher margins
Patient-specific formulations	Lactose-free, allergen-free options	Broader patient access
Regulatory filings	Leveraging excipient safety for faster approvals	Quicker market entry

Key Takeaways

• Excipient strategy for sertraline hydrochloride focuses on stability, bioavailability, and manufacturing efficiency.
• Innovations in excipient technology enable differentiation, extended patent life, and enhanced patient compliance.
• Commercial opportunities include controlled-release formulations, cost reduction, and broadened patient access.
• Regulatory trends favor transparency and safety profiles, influencing excipient selection.
• Companies should align excipient development with market needs, patent strategy, and manufacturing scalability.

FAQs

1. What are the primary excipients used in sertraline hydrochloride tablets?
Microcrystalline cellulose, povidone, croscarmellose sodium, and hypromellose are common excipients.

2. How can excipient choice impact drug stability?
Excipients influence chemical stability, moisture resistance, and shelf life, affecting product safety and efficacy.

3. What innovations in excipients can create competitive advantages?
Controlled-release polymers, taste-masking agents, and novel disintegrants improve formulation performance and patient experience.

4. Are there regulatory concerns associated with excipients in sertraline formulations?
Yes. Excipients must be well-characterized, approved, and non-interacting to meet regulatory standards.

5. How do excipient strategies influence patent protection?
Novel excipient systems can enable patent filings and extensions, delaying generic competition.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in FDA-Approved Human Drugs.
[2] European Medicines Agency. (2021). Reflection Paper on the Use of Excipients in Medicinal Products for Human Use.